Difamilast

Difamilast
Clinical data
Trade names	Moizerto, Adquey
Other names	OPA-15406
AHFS/Drugs.com
License data	US DailyMed: Difamilast;
Routes of; administration	Topical
Drug class	PDE4 inhibitor, dermatologic agent
ATC code	None;
Legal status
Legal status	US: ℞-only; JP: Rx-only;
Identifiers
	IUPAC name N-({2-[4-(difluoromethoxy)-3-(propan-2-yloxy)phenyl]-1,3-oxazol-4-yl}methyl)-2-ethoxybenzamide;
CAS Number	937782-05-3;
PubChem CID	57855696;
IUPHAR/BPS	9776;
DrugBank	DB14987;
ChemSpider	59718482;
UNII	T3U32GLJ0F;
KEGG	D11314;
ChEMBL	ChEMBL3989968;
Chemical and physical data
Formula	C23H24F2N2O5
Molar mass	446.451 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC1=CC=CC=C1C(=O)NCC2=COC(=N2)C3=CC=C(OC(F)F)C(OC(C)C)=C3;
	InChI InChI=1S/C23H24F2N2O5/c1-4-29-18-8-6-5-7-17(18)21(28)26-12-16-13-30-22(27-16)15-9-10-19(32-23(24)25)20(11-15)31-14(2)3/h5-11,13-14,23H,4,12H2,1-3H3,(H,26,28); Key:VFBILHPIHUPBPZ-UHFFFAOYSA-N;

Difamilast, sold under the brand name Moizerto among others, is a medication used for the treatment of atopic dermatitis.^[1] Difamilast is a non-steroidal topical phosphodiesterase 4 (PDE4) inhibitor.^[1] Difamilast was discovered and developed by Otsuka Pharmaceutical.^[2]^[3]^[4]^[5]